Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-03

Study Completion Date

2024-08-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

NCT02859948

Acute Myeloid Leukemia

UNKNOWN PHASE1

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01565668

Leukemia, Myeloid, Acute

COMPLETED PHASE2

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788

AML AML With Mutated NPM1 Hematologic Malignancy +9 more

RECRUITING PHASE1

A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

NCT04827069

Acute Myeloid Leukemia

COMPLETED PHASE1

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00923182

Leukemia, Lymphocytic, Chronic, B-Cell

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia (AML) Chronic Myelomonocytic Leukemia (CMML)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

This is an open-label Phase I/II, first-in-human (FIH), non-randomized, multi-center study conducted in two parts: a Phase I including patients with AML and CMML and a Phase II exploratory study comprising two parallel cohorts of AML FLT3 mutated patients.

The Phase II portion of the study is currently being conducted in EU only.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NMS-03592088

Phase I Dose Escalation

* Schedule A - Starting dose of 20 mg/day
* Schedule B - Starting dose of 120 mg/day

Only one dose level open for enrollment except EU backfill cohorts.

Phase II Dose Expansion (Exploratory) - (EU)

Recommended Phase II Dose (RP2D) of NMS-03592088 in Phase 1

* Cohort 1: Patients who have failed standard of care including venetoclax and gilteritinib based therapies
* Cohort 2: Patients who have failed standard of care

Group Type EXPERIMENTAL

NMS-03592088

Intervention Type DRUG

Route of administration: Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NMS-03592088

Route of administration: Oral

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with relapsed/refractory disease who have failed standard therapy or are unsuitable for standard treatment, with one the following confirmed diagnosis: AML as defined by the European LeukemiaNet (ELN)
* Patients with confirmed diagnosis of AML as defined by the 2022 ELN recommendations
* Patients must have failed standard of care.
* Adult (age ≥ 18 years) patients
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* The interval from prior antitumor treatment to time of NMS-03592088 administration should be at least 2 weeks for any agents other than hydroxyurea.
* All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTCAE version 5.0 Grade ≤1
* Adequate hepatic and renal function
* Patients must use highly effective contraception.
* Signed and dated IEC or IRB-approved informed consent form.

Exclusion Criteria

* Current enrollment in another interventional clinical study
* Diagnosis of acute promyelocytic leukemia or Breakpoint cluster region-Abelson (BCR-ABL)-positive leukaemia
* Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or cone biopsied in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
* Patients with known leukemia involvement of central nervous system (CNS)
* Hematopoietic stem cell transplantation (HSCT) within 3 months of treatment start and/or persistent non-hematologic toxicities of Grade ≥2 related to the transplant
* Active acute or chronic graft versus host disease (GVHD) requiring immunosuppressive treatment
* Patients with QTcF interval ≥ 480 milliseconds or with risk factors for torsade de pointes
* Pregnancy.
* Breast-feeding or planning to breast feed during the study or within 3 months after study treatment.
* Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
* Known active, life threatening or clinically significant uncontrolled systemic infection.
* Known active gastrointestinal disease
* Known active gastrointestinal ulcer
* Other severe or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
* Known diagnosis of myasthenia gravis

US only:

* Signs or symptoms of myasthenia gravis or stroke during screening
* Patients with myasthenia gravis specific autoantibodies or any known history of myasthenia gravis (MG) autoantibodies at screening window
* Concomitant medications with the potential to cause de novo myasthenia gravis, worsening of myasthenia gravis or cause myasthenia gravis-like symptoms
* Uncontrolled hypertension, atrial fibrillation or flutter, ventricular arrhythmia or receiving treatment for cardiac rhythm disorder or diabetes that is not adequately controlled

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No